L Girnita

List of Publications by Year in Descending Order

71 papers	3,427 citations	34 h-index	58 g-index
80 ext. papers	3,836 ext. citations	5.9 avg, IF	4.87 L-index

#	Paper	IF	Citations
71	Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth. *Cancer Research*, **2021**, 81, 501-514	10.1	5
70	Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. *Journal of the European Academy of Dermatology and Venereology* , **2021**, 35, 105-115	4.6	2
69	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. *Gastroenterology*, **2020**, 159, 2146-2162.e33	13.3	34
68	Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of 5.5 mm. *British Journal of Ophthalmology*, **2020**, 104, 26-32	5.5	17
67	Decrypting noncoding RNA interactions, structures, and functional networks. *Genome Research*, **2019**, 29, 1377-1388	9.7	57
66	Prediction of BAP1 Expression in Uveal Melanoma Using Densely-Connected Deep Classification Networks. *Cancers*, **2019**, 11,	6.6	15
65	Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey. *Cells*, **2019**, 8,	7.9	13
64	Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer. *Cells*, **2019**, 8,	7.9	27
63	Genome-Wide Screen for MicroRNAs Reveals a Role for miR-203 in Melanoma Metastasis. *Journal of Investigative Dermatology*, **2018**, 138, 882-892	4.3	24
62	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA induce myeloid malignancies via unique SNP-specific RNA mutations. *Genome Research*, **2018**, 28, 432-447	9.7	45
61	Blurring Boundaries: Receptor Tyrosine Kinases as functional G Protein-Coupled Receptors. *International Review of Cell and Molecular Biology*, **2018**, 339, 1-40	6	18
60	IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line. *Oncotarget*, **2018**, 9, 33871-33883	3.3	5
59	Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. *Oncogene*, **2017**, 36, 3274-3286	9.2	23
58	Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes. *Oncogene*, **2017**, 36, 5734-5744	9.2	21
57	Non-coding RNAs: the cancer genome dark matter that matters!. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 705-714	5.9	42
56	Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation. *Oncotarget*, **2017**, 8, 82256-82267	3.3	10
55	Differential Regulation of IGF-1 and Insulin Signaling by GRKs. *Methods in Pharmacology and Toxicology*, **2016**, 151-171	1.1	1

54	Estrogen Receptor Promotes Breast Cancer by Reprogramming Choline Metabolism. *Cancer Research*, **2016**, 76, 5634-5646	10.1	34
53	Chapter Seven - When Phosphorylation Encounters Ubiquitination: A Balanced Perspective on IGF-1R Signaling. *Progress in Molecular Biology and Translational Science*, **2016**, 141, 277-311	4	13
52	Targeting the IGF-1R: The Tale of the Tortoise and the Hare. *Frontiers in Endocrinology*, **2015**, 6, 64	5.7	41
51	The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?. *Growth Hormone and IGF Research*, **2015**, 25, 2-12	2	26
50	Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. *Cellular and Molecular Life Sciences*, **2014**, 71, 2403-27	10.3	102
49	Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. *Molecular Therapy - Nucleic Acids*, **2014**, 3, e172	10.7	3
48	Novel mechanisms of regulation of IGF-1R action: functional and therapeutic implications. *Pediatric Endocrinology Reviews*, **2013**, 10, 473-84	1.1	15
47	Insulin/insulin-like growth factor (IGF) stimulation abrogates an association between a deubiquitinating enzyme USP7 and insulin receptor substrates (IRSs) followed by proteasomal degradation of IRSs. *Biochemical and Biophysical Research Communications*, **2012**, 423, 122-7	3.4	26
46	Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. *Oncogene*, **2012**, 31, 352-65	9.2	72
45	Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing sarcoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 20620-5	11.5	53
44	Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 7055-60	11.5	74
43	Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). *PLoS ONE*, **2011**, 6, e14757	3.7	16
42	Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. *Neuro-Oncology*, **2010**, 12, 19-27	1	68
41	Aberrant intracellular IGF-1R beta-subunit makes receptor knockout cells (IGF1R-/-) susceptible to oncogenic transformation. *Experimental Cell Research*, **2009**, 315, 1458-67	4.2	7
40	Malignant solitary fibrous tumour of the orbit. *Acta Ophthalmologica*, **2009**, 87, 464-7	3.7	26
39	Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. *Oncogene*, **2008**, 27, 1629-38	9.2	61
38	Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. *Acta Ophthalmologica*, **2008**, 86 Thesis 4, 20-5	3.7	27
37	The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. *Acta Ophthalmologica*, **2008**, 86 Thesis 4, 26-34	3.7	12

36	Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. *Acta Ophthalmologica*, **2008**, 86 Thesis 4, 35-41	3.7	13
35	Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. *Acta Ophthalmologica*, **2008**, 86 Thesis 4, 42-9	3.7	8
34	Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. *Biochemical and Biophysical Research Communications*, **2008**, 368, 793-800	3.4	22
33	New picropodophyllin analogs via palladium-catalyzed allylic alkylation-Hiyama cross-coupling sequences. *Journal of Organic Chemistry*, **2008**, 73, 5795-805	4.2	28
32	Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. *Molecular Pharmacology*, **2008**, 73, 930-9	4.3	37
31	Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. *Cancer Research*, **2008**, 68, 5669-77	10.1	86
30	Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. *Investigative Ophthalmology and Visual Science*, **2008**, 49, 2620-6		34
29	Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. *Investigative Ophthalmology and Visual Science*, **2008**, 49, 2337-42		39
28	The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. *Journal of Vascular Surgery*, **2007**, 46, 108-15	3.5	18
27	Role of ubiquitination in IGF-1 receptor signaling and degradation. *PLoS ONE*, **2007**, 2, e340	3.7	56
26	Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. *Journal of Biological Chemistry*, **2007**, 282, 11329-38	5.4	100
25	The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. *Clinical Cancer Research*, **2006**, 12, 1383-91	12.9	96
24	IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). *Biochemical and Biophysical Research Communications*, **2006**, 347, 1059-66	3.4	18
23	Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. *Blood*, **2006**, 107, 655-60	2.2	108
22	IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. *Blood*, **2006**, 107, 669-78	2.2	123
21	The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. *Oncogene*, **2006**, 25, 3186-95	9.2	36
20	Role of insulin-like growth factor 1 receptor signalling in cancer. *British Journal of Cancer*, **2005**, 92, 2097-101	3.1	181
19	Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. *Investigative Ophthalmology and Visual Science*, **2005**, 46, 4372-5		54

18	{beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. *Journal of Biological Chemistry*, **2005**, 280, 24412-9	5.4	127
17	Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. *Clinical Cancer Research*, **2005**, 11, 4674-80	12.9	46
16	Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. *Clinical Cancer Research*, **2005**, 11, 206-16	12.9	46
15	c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 2075-82		61
14	Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. *Cancer Research*, **2004**, 64, 236-42	10.1	296
13	The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. *Oncogene*, **2004**, 23, 7854-62	9.2	132
12	Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in Multiple Myeloma Cells Using Selective IGF-IR Tyrosine Kinase Inhibitors.. *Blood*, **2004**, 104, 639-639	2.2	1
11	Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8247-52	11.5	165
10	CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. *Melanoma Research*, **2003**, 13, 325-37	3.3	38
9	Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene. *Oncogene*, **2003**, 22, 7628-31	9.2	25
8	Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 1-8		128
7	A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. *Oncogene*, **2000**, 19, 4298-301	9.2	58
6	Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. *Molecular and Cellular Endocrinology*, **2000**, 165, 131-7	4.4	38
5	Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. *Growth Factors*, **2000**, 17, 193-202	1.6	58
4	Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. *Anti-cancer Drug Design*, **2000**, 15, 67-72		25
3	Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. *Cancer Research*, **2000**, 60, 5278-83	10.1	63
2	Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. *Experimental Cell Research*, **1999**, 246, 38-46	4.2	26
1	The coexistence of atypical intraductal hyperplasias with breast carcinoma. *Romanian Journal of Morphology and Embryology*, **1998**, 44, 65-71	0.6	